CDK2 and benign prostatic hyperplasia: Nobiletin treatment significantly reduced the levels of CDK2, cyclin D1, and cyclin E in both BPH-1 and WPMY-1 cells, whereas CDK4 levels remained unchanged (Figures 3A,B).